Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa

• Published in: CNS & neurological disorders drug targets Vol. 13; no. 6; p. 953
• Main Authors: de Mello Schier, Alexandre R, de Oliveira Ribeiro, Natalia P, Coutinho, Danielle S, Machado, Sergio, Arias-Carrión, Oscar, Crippa, Jose A, Zuardi, Antonio W, Nardi, Antonio E, Silva, Adriana C
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2014
• Subjects: Anxiety - drug therapy; Cannabinoids - chemistry; Cannabinoids - therapeutic use; Cannabis - chemistry; Databases, Bibliographic - statistics & numerical data; Depressive Disorder - drug therapy; Humans; Medical Marijuana - therapeutic use
• ISSN: 1996-3181
• DOI: 10.2174/1871527313666140612114838

Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.